Trabedersen - Autotelic/Oncotelic Therapeutics
Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisenseLatest Information Update: 28 Apr 2024
At a glance
- Originator Antisense Pharma
- Developer Autotelic; Mateon Therapeutics; Oncotelic; Oncotelic Therapeutics; Oncotelic Therapeutics - Dragon Overseas Capital (JV)
- Class Antineoplastics; Antisense oligonucleotides; Antivirals; Immunotherapies; Oligodeoxyribonucleotides; Thionucleotides
- Mechanism of Action Transforming growth factor beta2 inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Yes - Malignant melanoma; Pancreatic cancer; Glioma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Glioblastoma
- Phase II/III Malignant melanoma; Pancreatic cancer
- Phase II COVID 2019 infections; COVID-19 pneumonia
- Phase I Cancer
- Clinical Phase Unknown Non-small cell lung cancer
- Preclinical Diffuse intrinsic pontine glioma
- No development reported Colorectal cancer; Ovarian cancer
- Discontinued Anaplastic astrocytoma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-19 pneumonia in USA (Parenteral)
- 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
- 04 Mar 2024 Phase-II/III clinical trials in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) (NCT06079346)
Development Overview
Introduction
Trabedersen is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) that specifically targets mRNA encoding transforming growth factor-β2 (TGFβ2), being developed by Autotelic, in partnership with Oncotelic Therapeutics (formerly Mateon Therapeutics), for the treatment of cancer and COVID-2019 infections and COVID-19 pneumonia. Trabedersen is believed to reverse TGF-'s immunosuppressive effects by reversing tumour induced immuno-blockade, reactivating the immune response, inhibiting tumour cell growth, and reducing migration and metastases. Trabedersen is a potent inhibitor of SAR-CoV-2 replication and also targets the lethal clinical sequelae of COVID-19, including pneumonia and fibrosis. Trabedersen through inhibition of TGFβ-Tgfbr1 pathway reduce internalisation of the epithelial sodium channel (ENaC) by alveolar epithelial cells which results in improved alveolar fluid reabsorption in ARDS, and reduction in pulmonary oedema in patients with severely ill COVID-2019 infections. Clinical development in glioblastoma is underway worldwide. Clinical development for pancreatic cancer and melanoma is underway in Germany. Clinical development for pancreatic cancer is ongoing at an unknown location. Clinical development for treatment of COVID-2019 infections and COVID-19 pneumonia is underway in Argentina and Peru. Preclinical development for the treatment of COVID-19 pneumonia and COVID-2019 infections is underway in the US. Preclinical development for diffuse intrinsic pontine glioma is ongoing in the US.
The proposed mechanism and actions for trabedersen against COVID-19 infections include inhibition of cellular binding, inhibition of viral replication and suppression of viral induced pneumonia [1] .
Development in anaplastic astrocytoma/glioblastoma was terminated at phase III, and later discontinued. No recent reports of development have been identified for clinical development in colorectal cancer in Germany.
Oncotelic is also developing a personalised dosing regimen of its TGFβ antisense nucleotide, designated as OT 201, which is under preclinical development (Oncotelic pipeline, September 2016).
Trabedersen originated with Antisense Pharma, which was renamed as Isarna Therapeutics in September 2013; subsequently the drug was acquired by Autotelic [2] .
In April 2019, Oncotelic was acquired by Mateon Therapeutics [3] .
In March 2021, Mateon Therapeutics has acquired Oncotelic and then changed its name to Oncotelic Therapeutics [4] .
As at October 2021, no recent reports of development had been identified for preclinical development in Glioblastoma (Combination therapy) in USA (IV, Infusion), preclinical development in Malignant-melanoma (Combination therapy) in USA (IV, Infusion), preclinical development in Ovarian-cancer (Combination therapy) in USA (IV, Infusion).
As at April 2024, no recent reports of development had been identified for preclinical development in COVID-19 pneumonia in USA (Parenteral), preclinical development in COVID-2019-infections in USA (Parenteral).
Company Agreements
In April 2022, Oncotelic Therapeutics announced the formation of a joint venture with Dragon Overseas Capital. This joint venture is known as GMP Biotechnology. This JV is for the discovery, development and commercialization of TGF-ß therapeutics against all pharmaceutical indications Oncotelic to receive up to $50 million on sale of the RPD voucher following marketing approval of OT-101 for DIPG. Dragon Overseas has agreed to invest cash and other assets with a value of approximately $27.6 million for 55% ownership of the JV, Oncotelic has Licensed OT-101 to the JV for a 45% ownership in the JV. [5] [6] [6]
In October 2022, Oncotelic Therapeutics and Biomedical Advanced Research and Development Authority (BARDA) signed a contract for the development of trabedersen (OT 101) under a project named trabedersen which is a transforming growth factor-beta (TGF-ß) therapeutics against long-term effects of respiratory distress post COVID-19. The goal of the project funded by BARDA is to demonstrate the potential efficacy of trabedersen against the long-term effects of respiratory distress following COVID-19. Its scope includes gathering long-term clinical data on COVID-19 patients in Peru and Argentina. Under contract number 75A50122C00066, the Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority have provided all or a portion of the funding for the research. [7]
In September 2017, Marina Biotech (Adhera Therapeutics) entered into an Intellectual Property Purchase Agreement with Novosom. Under the agreement, Marina Biotech sold to Novosom all of intellectual property estate related to Smarticles® liposomal-based delivery system including that acquired under the Original Purchase Agreement, for an aggregate purchase price of $US1 million. with the IP, Novosom also assigned third-party agreements and associated certain licenses and rights with respect to the Smarticles® IP, including the right to receive milestone and royalty payments, which were concluded by Marina. Novosom payed cash amount of $US45 000 in connection with the amendment to the IP Purchase Agreement. Earlier, in July 2010, Marina Biotech acquired the intellectual property of Novosom, for its Smarticles® liposomal-based delivery system in an all-stock transaction. The assets were acquired by Marina for approximately $US5 million in unregistered Marina common stock. Additional terms of the agreement were not disclosed. [8] [9]
In July 2017, Marina Biotech (now Adhera Therapeutics) entered into a license agreement with Oncotelic (now Oncotelic Therapeutics) under which the former licensed its SMARTICLES platform for the delivery of antisense DNA therapeutics and its conformationally restricted nucleotide (“CRN”) technology with respect to TGF-beta. Under the terms of the agreement, Oncotelic will invest $US250 000 in Marina at a share price of $0.51. Marina Biotech could receive sales milestones of up to $US90 million based on commercial sales of licensed products. Further details of the agreement were not disclosed. In addition, if Oncotelic determines to pursue further development and commercialisation of products under the agreement, Oncotelic will purchase shares of Marina Biotech's common stock for an aggregate purchase price of $US500 000, with the purchase price for each share of Marina common stock being the greater of $US0.51 or the volume weighted average price of the Marina common stock at the time of purchase. [10] [11] [4] [12]
In June 2020, Autotelic Bio and Mateon Thrapeutics (now Oncotelic Therapetics) entered into a licensing agreement for use of trabedersen in combination with interleukin-2 as an immune-oncology therapy. Mateon therapeutics completed its milestone payment to Autotelic Bio. Additionally, Mateon is entitled to profit sharing and royalties arising from the commercialization and/or licensing of OT-101/IL-2 by Autotelic Bio [13] [4]
In June 2020, Golden Mountain Partners and Mateon Therapeutics completed the research and services agreement entered on February 3, 2020. The collaboration will be conducting clinical development of OT-101, Artemisinin, and other antisense drug candidates for the treatment of COVID-19 infections. [14]
In October 2015, Isarna Therapeutics signed an asset sale and purchase agreement with Autotelic, whereby Autotelic gained full and worldwide rights to develop trabedersen. Financial terms of the agreement were not disclosed [15] .
Key Development Milestones
In March 2024, Oncotelic Therapeutics initiated the phase IIb/III STOP-PC study to compare the efficacy and safety of trabedersen (OT 101) in combination with FOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to FOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer (NCT06079346; OT-01-P201). The multicentre, open, parallel, prospective, randomized trial aims to enroll 468 patients at an unknown location [16] [17]
As at August 2023, Oncotelic Therapeutics in collaboration with Cromos Pharma plans to conduct a phase IIb/III trial for pancreatic cancer in 2H of 2023 [18] [19] [20] . Earlier, in January 2023, the Company submitted a clinical study protocol to the US FDA for the initiation of a phase IIb/III (P201) trial for OT 101 as a treatment for metastatic pancreatic cancer [21] .
As at September 2016, phase II/III development of trabedersen is ongoing for pancreatic cancer, melanoma and glioblastoma (Oncotelic pipeline, September 2016).
Monotherapy
Anaplastic astrocytoma/glioblastoma
In November 2022, Oncotelic Therapeutics submitted clinical trial protocol for initiation of phase I G101 trial in pediatric Diffuse Midline Glioma (DMG) (Glioblastoma) patients, administered intraventricularly [22] .
In December 2008, Isarna Therapeutics initiated a phase III trial to investigate the safety and efficacy of trabedersen in patients with recurrent or refractory anaplastic astrocytoma or secondary glioblastoma (SAPPHIRE; NCT00761280; EudraCT2007-005802-38; G005). The study was intended to enrol approximately 27 patients from sites in Europe, Canada, Mexico, and Asia. Trabedersen was to be compared with standard chemotherapy (temozolomide or BCNU) in the trial. The primary endpoint would be the survival rate at 24 months. However, the trial was discontinued in March 2012 due to lack of patient recruitment (no safety or efficacy issues) [23] [24] [25] .
In April 2003, Isarna Therapeutics initiated a dose finding phase II trial to evaluate the safety and efficacy of two doses of trabedersen compared to standard chemotherapy (temozolomide or PCV) in patients with recurrent or refractory anaplastic astrocytoma or secondary glioblastoma (NCT00431561; AP 12009-G004). The trial was completed in March 2009 and enrolled 141 patients in Austria, Georgia, Germany, India, Israel and Russia. Results from the study in 141 patients with recurrent or refractory glioma demonstrated that trabedersen administered intratumourally was well tolerated and equivalent to chemotherapy with temozolomide or PCV (combination therapy of procarbazine, lomustine and vincristine). In addition, a sub-population analysis demonstrated trabedersen improved overall response rate and survival in 39 patients with anaplastic astrocytoma. Results from a 24-month follow-up were reported in April 2010. In March 2019, data from the trial showed improved survival was achieved by repeated exposure to temozolomide/alkylating agent, which were presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019). This was further enhanced by trabedersen and consistent with the proposed MOA of trabedersen/Chemo as reactivation of immunity during TGF-β suppression and subsequent xenogenization by temozolomide [26] [24] [27] [28] [29] [30] [31] [32] .
Antisense was targeting approval of trabedersen in this indication in the EU where the product candidate has orphan drug status. The Scientific Advice Working Party of the EMEA had accepted the 24 month survival rate as the primary study endpoint for the phase III study. Given the rarity of the disease, the surrogate endpoint of 14 month progression rate would have been accepted as the endpoint for conditional approval in anaplastic astrocytoma by the EMEA, provided this was supported by the survival data [29] .
A good safety and tolerability profile was reported for trabedersen following a phase I/II clinical trial in Germany and Europe in mid-2002. There were no drug related clinically relevant adverse events and six of eighteen patients showed stabilisation or response [33] .
Diffuse intrinsic pontine glioma
In September 2019, Mateon Therapeutics announced that the US FDA granted Rare Pediatric Disease Designation to trabedersen for the treatment of diffuse intrinsic pontine glioma (DIPG) [34] .
Other solid tumours
In November 2011, Antisense Pharma completed an open-label phase I/II trial of trabedersen in patients with pancreatic carcinoma, malignant melanoma, or colorectal cancer (NCT00844064; AP 12009-P001; P-001). This trial was initiated in January 2005 and completed enrolment of 62 patients in Germany [35] . Oncotelic released results from the trial in April 2017, September 2016 and March 2016 [36] [37] [38] [39] [40] . In August 2017, the company presented the results of the trial at the 42nd European Society for Medical Oncology Congress (ESMO-2017) [41] . In March 2019, updated efficacy results from the trial were presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019) [42] . In September 2020, updated efficacy data from the trial was released by Mateon Therapeutics [43] .
The development plans for trabedersen were revised by Isarna in September 2013, with the focus on a Responder Patient Profiling Program (RPPP). The RPPP was assessing the genetic profile and responder biomarkers in patients with cancer to find a correlation between tumour biology and response to anti-TGF-β oligonucleotides and preclinical development was ongoing [2] . The company had reported in its June 2015 corporate presentation that it planned to advance the RPPP towards an IND/CTA.
In February 2013, Antisense revised its development plan for trabedersen to focus on the systemic intravenous administration. The decision was based on preliminary data from the SAPPHIRE trial showing serious adverse events that might be associated with the local administration of the compound in the trial. The decision was further supported by the data from a phase I/II trial in solid tumour where treatment was safe and well tolerated following intravenous administration of trabedersen. There were encouraging survival outcome data in patients with pancreatic cancer or malignant melanoma compared with historical controls. Antisense plans to conduct a phase II trial to investigate systemic intravenous trabedersen in the treatment of malignant melanoma, pancreatic cancer and other tumours.
Oncotelic released data from preclinical study of trabedersen in human melanoma xenograft in athymic nude mice, in February 2016 [44] .
In August 2011, trabedersen received approval from the FDS for treatment of stage IV malignant melanoma [45] .
In September 2009, both the EMEA and the FDA granted orphan drug status for trabedersen in the treatment of pancreatic carcinoma [46] .
In April 2002, Antisense Pharma received orphan drug status for the treatment of high-grade glioma in the EU. Orphan drug status was granted by the US FDA in July 2002 for the same indication.
Combination therapy
In August 2023, University of Washington in collaboration with Genentech and Oncotelic Therapeutics withdrawn a phase II trial prior to opening to accrual (NCT05935774; NCI-2023-04564; RG1123580). The trial was planned to be initiated in December 2023 to evaluate the efficacy of trabedersen in combination with atezolizumab in patients with advanced recurrent and metastatic non-small cell lung cancer (NSCLC) in USA [47] .
In February 2023, Oncotelic Therapeutics initiated its second investigator initiated studies (IIS) in a series of planned clinical studies. The company submitted to US FDA a protocol for the study with approximately 30 patients with non-small cell lung cancer in collaboration with the Fred Hutchinson Cancer Center and a large pharmaceutical company in the field of immuno-oncology (IO). The study will combine its oligodeoxynucleotide trabedersen (OT 101) and a US FDA approved anti-PD-L1 checkpoint inhibitor [48] [47] .
As of January 2022, OT 101 is undergoing a phase Ib trial in combination with IL-2 [49] [50] .
As of January 2022, multiple trials combining trabedersen (OT 101) with pembrolizumab are in development [49] .
In May 2022, Oncotelic Therapeutics announced the clearance of the phase II trial (M201) protocol for mesothelioma by the US FDA. In December 2021, Oncotelic Therapeutics announced that it has submitted clinical study protocol to the US FDA for the initiation of a phase II trial (M201) for trabedersen in combination with anti-PD-1 (pembrolizumab/Keytruda®) as a treatment for patients with malignant pleural mesothelioma (MPM) [51] [52] .
In March 2021, Oncotelic Therapeutics released pharmacodynamics data from a preclinical study in cancer for trabedersen in combination with Proleukin® [53]
In March 2021, Mateon Therapeutics received regulatory approval from the Ministry of Food and Drug Safety of Korea, and subsequently announced the initiation of a phase Ib clinical trial of a patented OT 101/IL-2 combination in solid tumours. The trial intends to confirm the safety and effectiveness of OT 101/IL-2 in solid cancer patients in cooperation with the UK global pharmaceutical company Clinigen Group. The trial is currently recruiting in South Korea [54] [50] .
In September 2017, Autotelic presented results from preclinical studies of trabedersen in combination with chemotherapy in tumour models at the 42nd European Society for Medical Oncology Congress (ESMO-2017) [55] .
In June 2020, a preclinical study OT 101 and IL-2 combination demonstrated good synergy against tumor xenograft models [13]
In March 2016, Oncotelic reported its plans to initiate multiple phase II combination trials followed by pivotal phase III registrational trials in several indications including pancreatic cancer, melanoma and glioblastoma [37] .
COVID-2019 infections and COVID-19 pneumonia
As of January 2022, Oncotelic Therapeutics reported that OT 101 has completed a phase II trial against COVID infection and demonstrated good efficacy [49] .
As of March 2023, Oncotelic Therapeutics completed the phase II C-001 trial for the treatment of patients with COVID-2019 infections and associated pneumonia. In June 2021, the enrollment of the trial was discontinued due to severe variants in Latin America, leading to exhaustion of medical care infrastructure. Trial completed randomisation of 32 out of 36 patients planned, on an intent to treat basis. Oncotelic stopped enrolment before full enrolment of the 18 patients needed for part 2, to determine the role of TGF-beta in the variants currently dominant in Latin America [56] . Earlier in December 2020, Mateon Therapeutics initiated a phase II C-001 trial to evaluate safety and efficacy of tradebersen in combination with standard of care for the treatment of COVID-2019 infections and associated pneumonia. The randomised, double blind, placebo-controlled trial is recruiting 72 patients in the Peru and Argentina [57] [58] . In March 2021, company announced that trial has completed enrollment in sentinel part 1 and part 2 COVID-19 patients and company intends to expand the trial with further enrollment of 18 patients in part 1 and part 2 of the trial. Targeted enrollment in part 1 with 18 patients has also been completed. No safety signals were observed in related to tradebersen in mild, moderate or severe COVID-19 infection. Once a complete data assessment of these 18 patients is competed by Oncotelic and its Data Safety Monitoring Board (DSMB), Oncotelic may continue to screen and enroll an additional cohort of 18 Part 1 patients [59] . In November 2021, efficacy data from this trial were released by Oncotelic Therapeutics [60]
In November 2020, Mateon Therapeutics announced that Instituto Nacional de Salud (INS), the regulatory agency of Peru, has approved C001 phase II trial for tradebersen for the treatment of patients with mild to severe COVID-19 infection. Earlier in June 2020, Mateon Therapeutics had announced that IQVIA was selected to manage the C001, a phase II randomised, controlled, multi-center clinical study of trabedersen. In the same month the company had announced that the IND for trabedersen (OT-101) for COVID19 was completed and they intend to initiate clinical trials against COVID-19 infections [61] . In April 2020, Mateon Therapeutics submitted an Investigational New Drug (IND) application with the US FDA seeking approval to evaluate trabedersen for the treatment of COVID-2019 infections. A pre-IND application was submitted by the company to the US FDA in the same month for COVID-19 infections. The company has requested US FDA to allow the referencing of OT-101’s oncology IND in order to streamline the IND submission for OT-101 against COVID-19 [62] [63] . Earlier In March 2020, Mateon Therapeutics released the preclinical results of trabedersen for the treatment of COVID-19 infections. Trabedersen showed significant activity against COVID-19 and SARS with safety index >500. Trabedersen inhibited virus binding to its target, thereby stopping the virus from replicating itself and stopping viral induced pneumonia, which often leads to patient complications. Trabedersen demonstrated potent activity against SARS-CoV-2 in the nanomolar range that was comparable to remdesivir, however, with higher safety index. Trabedersen avoids resistance mutations by targeting the host protein, TGF-ß, which could render vaccine and/or therapeutics against viral protein(s) ineffective. The proposed mechanism and actions for trabedersen against COVID-19 include inhibition of cellular binding, inhibition of viral replication and suppression of viral induced pneumonia [64] [65] [1] .
In March 2020, Mateon Therapeutics reported that it is developing trabedersen for the treatment of pneumonia associated with coronavirus infectious disease (COVID-2019) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The company believe that replication of SARS-Co-2 virus release TGF-β which further potentiate the viral replication. The progressive increase in TGF-β with increasing viral load results in increased permeability and failed fluid reabsorption in lungs, leading to persistent and severe pulmonary oedema and ARDS. TGF-β through Tgfbr1-mediated signaling pathway cause internalisation of the epithelial sodium channel (ENaC) by alveolar epithelial cells with marked reduction in the cell-surface abundance of ENaC on lung epithelial cells thereby rapidly and substantially impairing alveolar fluid reabsorption in ARDS patients, which culminate in pulmonary oedema. Thus, inhibition of TGF-β with trabedersen can reduse pulmonary oedema with inhibition of SARS-CoV-2 virus replication and improve ARDS in patients with severe COVID-2019 infections [66] [67] .
Financing information
In June 2020, Mateon Therapeutics secured $US2 million debt financing with Golden Mountain Partners to conduct clinical trial of OT 101 against COVID-19 infections [68] .
Patent Information
As of March 2021, Mateon Therapeutics has a patent for OT 101/IL-2 combination [54] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique''. The patent covers the candidate trabedersen. The patent is valid through April 2024 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "pharmaceutical composition''. The patent covers the candidate trabedersen. The patent is valid through December 2024 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment''. The patent covers the candidate trabedersen. The patent is valid through February 2025 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "use of low doses of oligonucleotides to TGF-β, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors''. The patent covers the candidate trabedersen. The patent is valid through May 2026 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "oligonucleotide-protein and/or peptide-polymer conjugates''. The patent covers the candidate trabedersen. The patent is valid through December 2027 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "dosage of oligonucleotides suitable for the treatment of tumors''. The patent covers the candidate trabedersen. The patent is valid through November 2029 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "combination of A chemotherapeutic agent and an inhibitor of the TGF-β system''. The patent covers the candidate trabedersen. The patent is valid through July 2030 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "combination therapy for treatment of pancreatic cancer''. The patent covers the candidate trabedersen. The patent is valid through February 2036 [69] .
As at December 2021, the United States Patent Office (USPTO) issued US patent with title, "compositions and methods for treating cancer''. The patent covers the candidate trabedersen. The patent is valid through February 2036 [69] .
Drug Properties & Chemical Synopsis
- Route of administration Intratumoural, IV, Parenteral
- Formulation Infusion, unspecified
- Class Antineoplastics, Antisense oligonucleotides, Antivirals, Immunotherapies, Oligodeoxyribonucleotides, Thionucleotides
- Target Transforming growth factor beta2; Virus replication
- Mechanism of Action Transforming growth factor beta2 inhibitors; Virus replication inhibitors
-
WHO ATC code
J05A-X (Other antivirals)
L01 (Antineoplastic Agents)
-
EPhMRA code
J5B (Antivirals, excluding anti-HIV products)
J5B9 (Antivirals, others)
L1 (Antineoplastics)
- Molecular formula C177 H225 N60 O94 P17 S17
- CAS Registry Number 925681-61-4
Biomarkers Sourced From Trials
| Indication | Biomarker Function | Biomarker Name | Number of Trials |
|---|---|---|---|
|
anaplastic astrocytoma |
Brief Title |
TGFB2 |
|
|
colorectal cancer |
Official Title |
TGFB2 |
|
|
colorectal cancer |
Outcome Measure |
TGFB2 |
|
|
glioblastoma |
Brief Title |
TGFB2 |
|
|
glioma |
Brief Title |
TGFB2 |
|
|
malignant melanoma |
Official Title |
TGFB2 |
|
|
malignant melanoma |
Outcome Measure |
TGFB2 |
|
|
pancreatic cancer |
Official Title |
TGFB2 |
|
|
pancreatic cancer |
Outcome Measure |
TGFB2 |
Biomarker
| Drug Name | Biomarker Name | Biomarker Function |
|---|---|---|
| Trabedersen - Autotelic/Oncotelic Therapeutics | TGFB2 | Brief Title, Official Title, Outcome Measure |
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Anaplastic astrocytoma | - | Late-stage disease, Recurrent, Second-line therapy or greater | Discontinued (III) | Argentina, Austria, Brazil, Canada, France, Germany, Hungary, India, Mexico, Poland, Russia, South Korea, Spain, Taiwan, USA, United Kingdom | Intratumoural / Infusion | Autotelic, Oncotelic | 07 Sep 2016 |
| Anaplastic astrocytoma | - | Late-stage disease, Recurrent, Second-line therapy or greater | Discontinued (II) | Georgia, Israel | Intratumoural / Infusion | Autotelic, Oncotelic | 07 Sep 2016 |
| COVID 2019 infections | - | - | Phase II | Argentina, Peru | Parenteral / unspecified | Mateon Therapeutics | 30 Dec 2020 |
| COVID 2019 infections | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Autotelic, Oncotelic Therapeutics | 28 Apr 2024 |
| COVID-19 pneumonia | - | - | Phase II | Argentina, Peru | Parenteral / unspecified | Mateon Therapeutics | 30 Dec 2020 |
| COVID-19 pneumonia | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Autotelic, Oncotelic Therapeutics | 28 Apr 2024 |
| Cancer | in combination with IL-2 | Combination therapy | Phase I | Unknown | IV / Infusion | Oncotelic Therapeutics | 19 Jan 2022 |
| Colorectal cancer | - | Second-line therapy or greater | No development reported (I/II) | Germany | IV / Infusion | Autotelic, Oncotelic | 11 Aug 2015 |
| Diffuse intrinsic pontine glioma | - | - | Preclinical | USA | Parenteral / unspecified | Oncotelic Therapeutics, Oncotelic Therapeutics - Dragon Overseas Capital (JV) | 04 Apr 2022 |
| Glioblastoma | - | Late-stage disease, Recurrent, Second-line therapy or greater | Phase III | Argentina, Austria, Brazil, France, Germany, Hungary, India, Poland, Russia, South Korea, Spain, Taiwan, USA, United Kingdom | Intratumoural / Infusion | Autotelic, Oncotelic Therapeutics | 01 Dec 2008 |
| Glioblastoma | - | Late-stage disease, Recurrent, Second-line therapy or greater | Phase II/III | Georgia, Israel | Intratumoural / Infusion | Autotelic, Oncotelic Therapeutics | 07 Sep 2016 |
| Glioblastoma | - | Combination therapy | No development reported (Preclinical) | USA | IV / Infusion | Autotelic | 28 Oct 2021 |
| Malignant melanoma | - | Second-line therapy or greater | Phase II/III | Germany | IV / Infusion | Autotelic, Oncotelic Therapeutics | 07 Sep 2016 |
| Malignant melanoma | - | Combination therapy | No development reported (Preclinical) | USA | IV / Infusion | Autotelic | 28 Oct 2021 |
| Non-small cell lung cancer | - | Combination therapy | Clinical Phase Unknown | USA | Parenteral / unspecified | Oncotelic Therapeutics | 06 Feb 2023 |
| Ovarian cancer | - | Combination therapy | No development reported (Preclinical) | USA | IV / Infusion | Autotelic | 28 Oct 2021 |
| Pancreatic cancer | - | Second-line therapy or greater | Phase II/III | Germany | IV / Infusion | Autotelic, Oncotelic Therapeutics | 07 Sep 2016 |
| Pancreatic cancer | - | Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater | Phase II/III | Unknown | IV / Infusion | Oncotelic Therapeutics | 04 Mar 2024 |
Orphan Status
| Indication | Patient Segment | Country | Organisation | Event Date |
|---|---|---|---|---|
| Glioma | - | European Union | Autotelic | 18 Apr 2002 |
| Glioma | - | USA | Autotelic | 22 Jul 2002 |
| Malignant melanoma | Late-stage disease | USA | Oncotelic Therapeutics | 22 Aug 2011 |
| Pancreatic cancer | - | European Union | Autotelic | 14 Sep 2009 |
| Pancreatic cancer | - | USA | Autotelic | 14 Sep 2009 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Antisense Pharma | Originator | Germany |
| Autotelic | Owner | USA |
| Oncotelic Therapeutics | Licensee | USA |
| GMP Biotechnology | Sub-licensee | Hong-Kong |
| Adhera Therapeutics | Technology Provider | USA |
| novosom AG | Technology Provider | Germany |
| Golden Mountain Partners | Collaborator | USA |
| Mateon Therapeutics | Collaborator | USA |
| Biomedical Advanced Research and Development Authority | Collaborator | USA |
Scientific Summary
Pharmacokinetics
Results of the phase I/II trial of trabedersen in patients with pancreatic cancer demonstrated increasing peak levels of IL-8 and IL-15 response on day 2 of trabedersen treatment. ANCOVA models for two feedback interactions with pharmacokinetics (PK) parameters showed significant model fits (F3,7 = 7.89, P = 0.012 for simulated Vz mean; F3,7 = 8.18, P = 0.011 for simulated Cl mean) and the interaction effects resulted in lower p-values for the correlation of overall survival (OS) versus IL-8 levels [41] . The PK profile of trabedersen, described by a two-compartment model, showed large distribution of the drug in the peripheral tissues. The influence of age, gender, BMI, height, cancer type and treatment schedule on the PK of trabedersen was not identified. Total body clearance observed was 0.17 mL/h, distribution volume of the central compartment was 4.69L, inter-compartmental clearance was 3.31 L/h and distribution volume of the peripheral compartment was 5046.44 L. Body weight was identified as a covariate on trabedersen inter-compartmental clearance, with KBW as -ve 1.48. With exclusion of protocol deviations, a total of 1 444 plasma sample concentration data, obtained from a phase I/II trial, from 100 patient cycles were examined. The study evaluated the safety and tolerability of trabedersen in 61 patients with pancreatic cancer (n = 37), malignant melanoma (n = 19) and colorectal carcinoma (n = 5) [36] [35] .
Adverse Events
Glioblastoma and anaplastic astrocytoma
Trabedersen was well tolerated in a phase IIb trial in 145 patients with recurrent or refractory glioblastoma, including 39 patients with anaplastic astrocytoma (AA). Patients received chemotherapy (N=33, AA patients=12), or trabedersen 10µM (N=28, AA=12) or 80µM (N=34, AA=15) via convection-enhanced delivery for up to 11 2-week cycles (7 days receiving treatment, followed by 7 days off). In the total population, drug related serious adverse events were observed in only three patients in the trabedersen 80µM group. In the AA subpopulation, there was a higher incidence of SAEs in the trabedersen groups (67% each) compared with the control group (25%), but these were often procedure related and mostly reversible; no serious adverse events were drug related. Two cases of neutropenia in the 90 patients was reported in trabedersen group versus 8, 10, and 8 patients with leukopenia, neutropenia and thrombocytopenia, respectively, among 45 patients treated with temozolomide (2% vs. 56%, p < 0.0001) [26] [29] [31] [30] [79] [33] [32] .
In three phase I/II studies, 27 adult patients with recurrent high-grade glioma and MRI evidence of tumour progression received a 113-fold dose escalation of trabedersen. The drug was administered by convection enhanced delivery, using an indwelling pump system. All doses were rated as safe by an independent Data and Safety Monitoring Board. Six patients had adverse events which were possibly related to treatment. There were no changes in haematological parameters or other laboratory values [83] .
Solid tumours
Trabedersen had a good safety and tolerability profile, based on interim results from a phase I/II trial in patients pancreatic cancer, malignant melanoma and colorectal cancer. At the time of the interim analysis, 25 patients in 6 cohorts had been treated in two dosing regimens. The maximum tolerated dose was established as 160 mg/m2/day, when trabedersen is given via IV infusion for the first 7 days of a 14 day cycle. Dose limiting toxicities, including two grade 3 thrombocytopenia and grade 3 exanthema, were observed at the 240 mg/m2/day dose level. In the second dosing schedule, trabedersen IV is given in the first 4 days of a 14 day cycle; dose escalation was ongoing in this schedule at the time of interim analysis [78] [39] . Additional data from this phase I/II trial showed that trabedersen was associated with a maximum tolerated dose (primary endpoint) of 160 mg/m2/day in the 7 days on-7 days off schedule and 140 mg/m2/day in the 4 days on-10 days off schedule in patients with pretreated advanced pancreatic cancer, colorectal cancer or malignant melanoma. Non-serious, moderate and transient thrombocytopenia was the only expected adverse reaction observed [73] .
Animal toxicology
After short-term infusion of trabedersen 5-160 mg/kg to cynomolgus monkeys there were no observed adverse effects reported for cardiovascular, clotting and haematological parameters. In mice, a single IV bolus dose of trabedersen was also well tolerated [85] [87] .
Pharmacodynamics
Summary
Treatment with trabedersen as a single agent significantly reduced lymph node metastasis (p = 0.023), tumour growth (p = 0.0084), and tumour angiogenesis (p < 0.0001) in mice model of human L3.6pl pancreatic cancer (PAC), as compared with untreated control. Trabedersen, in combination with dacarbazine (DTIC), demonstrated synergy in tumour growth inhibition and increased survival in human metastatic C8161 melanoma model (p = 0.038), as compared with DTIC alone. Synergistic effects in tumour growth inhibition and increased survival were also reported with combination therapy of trabedersen and paclitaxel (PTX) in SC glioblastoma (U87) (p = 0.001) and SC ovarian (SKOV-3) tumour models (p < 0.05), as compared with PTX alone. Trabedersen and gemcitabine combination therapy did not demonstrate synergy in PAC model. The combination regimen tested was effective and achieved significant antitumour activity at HED of 80 mg/m2/day, which is well below the optimised clinical dose used for intravenous infusion of patients at 140 mg/m2/day [55] .
Treatment with trabedersen resulted in antitumour activity in a mouse model of metastatic pancreatic cancer. A significant reduction in tumour weight (0.7 versus 1.4g, p=0.0084) and cell proliferation (p=0.028) occurred in the treatment arm relative to control animals. Furthermore, lymph node (2/10 mice) and liver metastasis (4/10) was lower in the treatment group than the control group (7/9 and 5/9 mice, respectively). Tumours showed a significant reduction in angiogenesis in the treatment group (p=0.0001) [75] .
Trabedersen efficiently targeted colorectal cancer cells and significantly reduced TGF-β2 expression in a dose-dependent manner. In functional assays, trabedersen inhibited colorectal carcinoma cell proliferation by up to 60% compared with controls. Trabedersen also reversed TGF-β2-mediated immunosuppression in an allogenic system with WiDr cells targeted by IL-2-activated peripheral blood mononuclear cells (LAK cells) derived from healthy donors. LAK cell cytoxicity was increased in a donor-dependent manner up to 190% after treatment with trabedersen [77] .
Tumour cells treated with trabedersen secreted reduced amounts of TGFβ2 and trabedersen abrogated TGFβ-dependent mechanisms of tumour progression. Moreover, when human glioma cells were exposed to trabedersen, the anti-tumour response of LAK effector cells was enhanced. This effect is related to downregulation of TGFβ synthesis in vitro. Glioma cell proliferation and migration was also inhibited by trabedersen in a dose dependent manner [86] .
TGFβ2 secretion was inhibited in several human pancreatic cancer cell lines by trabedersen. Trabedersen reversed TGFβ2-mediated immunosuppression, reduced pancreatic cancer cell proliferation up to 76% in a dose-dependent manner, and completely blocked pancreatic cancer cell migration [81] .
In a human glioma cell line (A-172), trabedersen potently inhibited TGFβ2 expression and barely affected TGFβ1 expression when the cell culture medium contained serum. However, under serum-free conditions, both isoforms were inhibited. The inhibitory effects of trabedersen on TGFβ1 expression was reversed by addition of rhTGFβ2. Specific inhibition of TGFβ2 expression by trabedersen down-regulated TGFβ1 and also interrupted the cross-regulatory loop whereby TGFβ induces the expression of TGFβ1 [74] .
Trabedersen inhibited TGF-2 secretion and proliferation of human malignant melanoma cell cultures (Mel-Juso, MER 116, and RPMI 7951) and cell migration from MER spheroids. Combination of trabedersen and dacarbazine (DTIC) induced a synergistic effect (p<0.001) on tumour inhibition in the C8161 melanoma xenograft in athymic nude mice [44] .
Pharmacodynamics data obtained from a preclinical study for trabedersen in combination with low doses of Proleukin indicated that decreased cancer cell viability in solid cancer cell lines. In a humanised NGS mouse model with the combination therapy, melanoma and triple negative breast cancer tumour growth was reported to be delayed. A statistically significant delay in tumour growth was observed in tradebersen treatment alone or intraleukin-2 alone group. In trabedersen treated group, tumour infiltrating lymphocyte population was increased, and FoxP3+ regulatory T cell population in blood and tumour microenvironment was decreased [53] .
In an in vitro antiviral testing, trabedersen showed an 50% effective concentration (EC50) of 7.6 µg/mL and was not toxic at the highest dose of 1000 µg/mL giving a safety index (SI) value of >130, which is considered highly active [1] .
Therapeutic Trials
Glioblastoma and anaplastic astrocytoma
Phase II
Trabedersen showed equal efficacy to chemotherapy with temozolomide or PCV (combination therapy of procarbazine, lomustine and vincristine) in an open label, randomised phase IIb trial of 145 patients with recurrent or refractory high grade glioblastoma. Patients either received chemotherapy or trabedersen 10 or 80µM intratumourally via convection-enhanced delivery for up to 11, 2-week cycles comprising 7 days treatment, followed by 7 days off. The overall response rate (complete or partial response) at 12 months, based on 134 evaluable patients was 3%, 7%, and 0% in the chemotherapy (N=33), trabedersen 10 (N=28) and 80µM groups (N=34), respectively. In addition, there were more survivors after 1.5 and 2 years in the trabedersen groups compared with the control group. The 2-year survival rates were 83%, 53% and 42%, respectively, in the trabedersen 10µMol, 80µMol and standard chemotherapy groups, respectively. Furthermore, the duration of response was approximately three-times longer in the 10µMol group than in the standard chemotherapy group (29.1 vs 8.0 months) and the median survival duration in the trabedersen 10µMol group was 17.4 months [76] . In a subpopulation analysis of patients with recurrent anaplastic astrocytoma, trabedersen therapy was associated with a higher survival rate and overall response rate compared with the chemotherapy analysis. The overall response rate at 14 months and survival rate at 24 months was 34% and 83% in the trabedersen 10µM group (N=12), respectively, 20% and 53% in the trabedersen 80 µM group (N=15), respectively and 0% and 42% in the control group (N=12), respectively. Furthermore, the median survival time was 37.2 and 21.7 months in the trabedersen 10µM and control groups, respectively. In the trabedersen 10µM group, there was a steady increase in overall tumour response over 14 months, whereas the response rate in the chemotherapy group decreased from 25% to 0% [24] [27] [29] [30] [39] [79] [80] [32] .
In a phase I/II dose escalation trial of trabedersen showed that six out of 18 patients achieved an objective response or disease stabilisation [33] . Another patient had a complete response after one course without any other anti-tumour therapy [84] .
In three phase I/II studies, 27 adult patients with recurrent high-grade glioma and MRI evidence of tumour progression received a 113-fold dose escalation of trabedersen. The drug was administered by convection enhanced delivery, using an indwelling pump system. In the 20 evaluable patients, median overall survival results for trabedersen therapy versus literature values for temozolomide therapy were 77.0 vs 42 weeks for anaplastic astrocytoma and 42.4 vs 32 weeks for glioblastoma. 13 patients who had received temozolomide prior to trabedersen had median overall survival results of 106.4 weeks for anaplastic astrocytoma and 46.1 weeks for glioblastoma [83] . In follow-up results, the median overall survival time of patients from start of the first trabedersen treatment was 90 weeks and 44 weeks for anaplastic astrocytoma and glioblastoma respectively compared to 42 weeks and 32 weeks for those receiving temozolomide therapy for anaplastic astrocytoma and glioblastoma respectively. The mean overall survival for 16 patients that received temozolomide before trabedersen was 146.6 weeks for anaplastic astrocytoma and 46.1 weeks for glioblastoma. One patient had a complete response in all tumour sites after one cycle of trabedersen. He survived for 195 weeks until his death due to myocardial infarction. A similar tumour reduction of more than 80% for a second patient has been documented. This patient is still alive and has to date received 12 cycles of trabedersen [82] .
Other solid tumours
Updated results from the trial demonstrated reduction in IL-6 levels in more than 50% of patients following first cycle of dosing of trabedersen. Patients who exhibited a rebound effect following termination of treatment in cycle 1 is decreased again on subsequent administration of trabedersen in cycle 2. All the patients exhibited elevated IL-6 levels on disease progression [43] . Updated results from a phase I/II trial in patients with pancreatic cancer demonstrated that the median OS (mOS) for 18 second-line patients (OT 101/SC) was 9.4months compared with 2.8 months in 19 patients on OT 101/best supportive care (BSC) (p = 0.0004). Patients with only liver metastasis had a mOS of 9.5 months versus 4.7 months(p = 0.0077) in those with liver metastasis and others. Complete response beyond 77.3 months was reported in one patient and another had stable disease with OS of 40.3 months in the former group. For liver metastasis only group with OT 101/SC OS was 12.4 months compared with 1.9 months (p = 0.0006). Disease control (DC) was reported in 16 of 37 patients with a mOS of 9.7 months versus 3 months (p < 0.0001). In the DC group OS was higher for with OT-101/SC being 11.8 months versus 5 months (p = 0.0021). A spike was observed in IL-8 level which returned to basal level when the treatment was stopped. The R2 relating the IL-8 spike and OS were 0.8522 (p = 0.0011) and 0.9895 (p = 0.0053) for patients treated subsequently with SC and BSC, respectively [42] . Earlier it was shown that When stratified for patients with and without chemotherapy, R2 increased to 0.99 and 0.77 respectively. Similar results were observed for IL-15, with R2 = 0.93 in patients with chemotherapy and R2 = 0.50 in those without therapy [41] . Anti-cancer activity was demonstrated in patients with pancreatic carcinoma, malignant melanoma and colorectal cancer. In the first dosing schedule, trabedersen was administered for the first 7 days of a 10 day cycle, the maximum tolerated dose (MTD) was established as 160 mg/m2/day, whereas MTD was not reached on 4/10 regimen (n = 27) even at highest dose of 330 mg/m2/d. There were 16 second-line patients and 11 third-line and beyond on 4/10 regimen. The progression free survival/overall survival (PFS/OS) of the second line patients in months were: 1.87/5.60 (n = 6), 1.87/9.93 (n = 11) and 2.72/11.80 (n = 5) at increasing mean dose of 140, 167 and 196 mg/m2/d, respectively. The OS of 9.93 and 11.80 months were higher (range = 2.50-9.20/median = 5.50 months). The corresponding progression free survival (PFS) values were in line (range = 0.00-7.65/median = 2.43 months). The OS of 4/10 cohort treated with subsequent chemotherapies was 14.7 and 2.93 months with and without subsequent chemotherapies, p = 0.0023. Chemotherapy on second line followed with subsequent trabedersen 4/10 regimen as third line was ineffective with OS of 2.80 months (n = 9) versus 9.93 months (n = 11), p = 0.046. Of the five malignant melanoma patients treated with trabedersen, one from the first schedule showed stable disease and lived for 13.8 months, three patients from the second schedule are still alive. Median overall survival (OS) for advanced pancreatic carcinoma patients in the first schedule was 6.8 months; one patient showed a complete response and is still alive 45.6 months (as of Feb 2009) after receiving trabedersen therapy. The median OS for pancreatic carcinoma patients in the first cohort of five patients in the second schedule is 13.4 months (as of Aug 2009); one patient is still alive with stable disease 19 months (as of April 2009) after start of study treatment. Additional data showed that trabedersen administered at the maximum tolerated dose of 160 mg/m2/day (7 days on 7 days off) or 140 mg/m2/day (4 days on, 10 days off) was active in all patients. Updated results from the trial showed an IL-8 spike during first cycle of therapy resulting in improved overall survival in pancreatic cancer patients treated with trabedersen [37] [72] [46] [78] [39] [73] [35] .
In a phase I/II melanoma study, trabedersen treatment resulted in improved overall survival (OS) which was not supported by progression-free survival (PFS). The effect was observed when chemotherapies were used as subsequent therapies following trabedersen treatment [38] .
Results from phase II C001 trial demonstrated that the overall survival improved significantly improved from 4 day for placebo to 14 day OT-101 among critically ill COVID-19 patients. End of treatment- day 7-mortality for the entire study population was 4.5% OT-101 versus 20% placebo. Incidence of >96% viral load knockdown on end of treatment- day 7- was 89% for OT-101 versus 67% for placebo [60] [57]
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 31 Dec 2023 | Trial Update | Oncotelic plans to initiate enrollment of phase II trial for COVID 2019 infections in Brazil in 2023(NCT04801017) (700335003) [70] | 30 Dec 2022 |
| 31 Dec 2023 | Trial Update | Oncotelic Therapeutics plans a phase IIb/III trial for Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease) in 2H of 2023 (9389839) (700306792) | 23 May 2023 |
| 01 Dec 2023 | Trial Update | Oncotelic Therapeutics plans the phase IIb/III STOP-PC trial in Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease, Unresectable/Inoperable, Late stage disease) (IV) in December 2023 (NCT06079346) (700368023) | 07 Mar 2024 |
| 31 Dec 2022 | Trial Update | Oncotelic Therapeutics plans a multiple phase II trials combination of trabedersen with a PD-1 inhibitor throughout 2021-2022 [71] | 22 Oct 2021 |
| 31 Dec 2020 | Trial Update | Mateon Therapeutics announce intention to advance phase I clinical trials of OT 101/IL-2 combination in 2020 [13] | 21 Jan 2022 |
| 30 Jun 2020 | Trial Update | Mateon Therapeutics plans a phase II trial for COVID-2019 infections and COVID-19 pneumonia in USA and Peru in June 2020 (700321265) [61] | 06 Jan 2021 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Apr 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in COVID-19 pneumonia in USA (Parenteral) Updated 28 Apr 2024 |
| 28 Apr 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral) Updated 28 Apr 2024 |
| 04 Mar 2024 | Phase Change - II/III | Phase-II/III clinical trials in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) (NCT06079346) [17] Updated 13 Mar 2024 |
| 17 Oct 2023 | Trial Update | Oncotelic Therapeutics plans the phase IIb/III STOP-PC trial in Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease, Unresectable/Inoperable, Late stage disease) (IV) in December 2023 (NCT06079346) Updated 07 Mar 2024 |
| 25 Aug 2023 | Trial Update | University of Washington in collaboration with Genentech and Oncotelic Therapeutics plans a phase II trial for Non-small cell lung cancer (Metastatic disease, combination therapy, Recurrent, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05935774) Updated 15 Sep 2023 |
| 23 May 2023 | Trial Update | Oncotelic Therapeutics plans a phase IIb/III trial for Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease) in 2H of 2023 [19] Updated 23 May 2023 |
| 16 Mar 2023 | Trial Update | Oncotelic Therapeutics completes a Phase-II clinical trials in COVID-19 pneumonia in Argentina, Peru (Parenteral) (Oncotelic Therapeutics website, March 2023) Updated 02 Apr 2023 |
| 16 Mar 2023 | Trial Update | Oncotelic Therapeutics completes a Phase-II clinical trials in COVID-19 infections in Argentina, Peru (Parenteral) (Oncotelic Therapeutics website, March 2023) Updated 02 Apr 2023 |
| 06 Feb 2023 | Phase Change - Clinical | Clinical trials in Non-small cell lung cancer (Combination therapy) in USA (Parenteral) [48] Updated 10 Feb 2023 |
| 06 Feb 2023 | Regulatory Status | Oncotelic Therapeutics submits a protocol for the clinical study in Non-small cell lung cancer to US FDA [48] Updated 10 Feb 2023 |
| 25 Jan 2023 | Regulatory Status | Oncotelic Therapeutics submits clinical study protocol to the US FDA for the initiation of a phase IIb/III trial for Pancreatic cancer [21] Updated 30 Jan 2023 |
| 25 Jan 2023 | Trial Update | Oncotelic Therapeutics plans a phase IIb/III trial for Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease) [21] Updated 30 Jan 2023 |
| 30 Dec 2022 | Regulatory Status | 9377424- FE updated, planned trial HE added Updated 30 Dec 2022 |
| 28 Dec 2022 | Trial Update | Oncotelic plans to initiate enrollment of phase II trial for COVID 2019 infections in Brazil in 2023(NCT04801017) [70] Updated 30 Dec 2022 |
| 28 Dec 2022 | Trial Update | Oncotelic Therapeutics plans a phase III trial for Pancreatic cancer (IV, Infusion) [70] Updated 30 Dec 2022 |
| 28 Dec 2022 | Trial Update | Oncotelic Therapeutics plans the phase G101 II/III trial for Glioma (Second-line or greater therapy, In adolescents, In children) (Intraventricular) [70] Updated 30 Dec 2022 |
| 08 Nov 2022 | Regulatory Status | Oncotelic Therapeutics submits clinical trial protocol to the US FDA for initiation of phase I G101 trial in Glioblastoma [22] Updated 14 Nov 2022 |
| 12 Oct 2022 | Company Involvement | Oncotelic Therapeutics signs a BARDA contract for the development of trabedersen in COVID-19 infections [7] Updated 14 Oct 2022 |
| 25 May 2022 | Regulatory Status | US FDA approves clearance of the phase II trial application for trabedersen in Mesothelioma [51] Updated 27 May 2022 |
| 25 May 2022 | Trial Update | Oncotelic Therapeutics plans a phase II (M201) trial for Mesothelioma (Combination therapy) in USA [51] Updated 27 May 2022 |
| 04 Apr 2022 | Licensing Status | Oncotelic out-licenses trabedersen to Oncotelic Therapeutics - Dragon Overseas Capital (JV) [5] Updated 06 Apr 2022 |
| 04 Apr 2022 | Phase Change - Preclinical | Preclinical trials in Diffuse intrinsic pontine glioma in USA (Parenteral) as of April 2022 [5] [34] Updated 06 Apr 2022 |
| 19 Jan 2022 | Phase Change - I | Phase-I clinical trials in Cancer (Combination therapy) (IV) prior to January 2022 [49] Updated 21 Jan 2022 |
| 19 Jan 2022 | Trial Update | Oncotelic Therapeutics completes a phase II trial of OT 101 in COVID-19 infection, prior to January 2022 [49] Updated 21 Jan 2022 |
| 05 Dec 2021 | Scientific Update | Efficacy data from phase II C001 trial in COVID-2019-infections were released by Oncotelic Therapeutics [60] Updated 05 Dec 2021 |
| 01 Dec 2021 | Regulatory Status | Oncotelic Therapeutics submits clinical study protocol to US FDA for Mesothelioma (Combination therapy) in December 2021 [52] Updated 03 Dec 2021 |
| 01 Dec 2021 | Trial Update | Oncotelic Therapeutics plans a phase II trial for Mesothelioma (Combination therapy, Treatment-resistant, Second-line or greater therapy) in USA [52] Updated 03 Dec 2021 |
| 28 Oct 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Glioblastoma(Combination therapy) in USA (IV, Infusion) Updated 28 Oct 2021 |
| 28 Oct 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Malignant-melanoma(Combination therapy) in USA (IV, Infusion) Updated 28 Oct 2021 |
| 28 Oct 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Ovarian-cancer(Combination therapy) in USA (IV, Infusion) Updated 28 Oct 2021 |
| 28 Oct 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Pancreatic-cancer(Combination therapy) in USA (IV, Infusion) Updated 28 Oct 2021 |
| 20 Oct 2021 | Trial Update | Oncotelic Therapeutics plans a multiple phase II trials combination of trabedersen with a PD-1 inhibitor throughout 2021-2022 [71] Updated 22 Oct 2021 |
| 15 Jun 2021 | Trial Update | Oncotelic Therapeutics discontinues enrolment in its phase II trial in COVID-2019 infections and COVID-19 pneumonia in Argentina, Peru due to severe variants in Latin America [56] Updated 21 Jun 2021 |
| 19 Apr 2021 | Scientific Update | Pharmacodynamics data from a preclinical study in Cancer was released by Oncotelic [53] Updated 25 Apr 2021 |
| 30 Mar 2021 | Company Involvement | Mateon Therapeutics has acquired Oncotelic and then changed its name to Oncotelic Therapeutics Updated 30 Apr 2021 |
| 15 Mar 2021 | Patent Information | Mateon Therapeutics has patent protection for OT 101/IL-2 combination before March 2021 [54] Updated 23 Mar 2021 |
| 15 Mar 2021 | Regulatory Status | Mateon Therapeutics receives approval from the Ministry of Food and Drug Safety of Korea for initiation of phase Ib trial in Solid tumours (Combination therapy) [54] Updated 23 Mar 2021 |
| 15 Mar 2021 | Trial Update | Mateon Therapeutics initiates a phase Ib trial in Solid tumours (Combination therapy) in South Korea [54] Updated 23 Mar 2021 |
| 31 Dec 2020 | Patent Information | Oncotelic Therapeutics has patents protection for Trabedersen in USA [69] Updated 12 May 2021 |
| 31 Dec 2020 | Trial Update | Oncotelic Therapeutics plans a phase III trial for Pancreatic cancer in China [69] Updated 12 May 2021 |
| 30 Dec 2020 | Phase Change - II | Phase-II clinical trials in COVID-19 pneumonia in Argentina, Peru (Parenteral) [58] Updated 12 Jan 2021 |
| 30 Dec 2020 | Phase Change - II | Phase-II clinical trials in COVID-2019 infections in Argentina (Parenteral) [58] Updated 06 Jan 2021 |
| 30 Dec 2020 | Phase Change - II | Phase-II clinical trials in COVID-2019 infections in Peru (Parenteral) [58] Updated 06 Jan 2021 |
| 04 Nov 2020 | Regulatory Status | Instituto Nacional de Salud (INS) approves a phase II C001 trial in COVID-19 pneumonia and COVID-2019 infections in Peru Updated 12 Nov 2020 |
| 23 Sep 2020 | Scientific Update | Efficacy data from a phase I/II trial in Solid tumour released by Mateon Therapeutics [43] Updated 23 Sep 2020 |
| 22 Jun 2020 | Licensing Status | Golden Mountain Partners (GMP) and Mateon Therapeutics complete a research and services agreement for clinical development in COVID-19 infections [14] Updated 25 Jun 2020 |
| 22 Jun 2020 | Trial Update | Mateon Therapeutics in collaboration with Golden Mountain Partners plans for clinical development of OT 101 in COVID-19 infections [14] Updated 25 Jun 2020 |
| 10 Jun 2020 | Trial Update | Mateon Therapeutics announce intention to advance phase I clinical trials of OT 101/IL-2 combination in 2020 [13] Updated 21 Jan 2022 |
| 10 Jun 2020 | Licensing Status | Autotelic Bio in-licenses OT 101 to use in combination with IL-2 [13] Updated 16 Jun 2020 |
| 01 Jun 2020 | Trial Update | Mateon Therapeutics plans a phase II trial for COVID-2019 infections and COVID-19 pneumonia in USA and Peru in June 2020 [61] Updated 06 Jan 2021 |
| 01 Jun 2020 | Regulatory Status | US FDA approves IND application for trabedersen in COVID-2019 infections [61] Updated 06 Jun 2020 |
| 30 Apr 2020 | Trial Update | Mateon Therapeutics plans a phase II trial for COVID-2019 infections and associated Pneumonia in USA [62] Updated 30 Apr 2020 |
| 27 Apr 2020 | Regulatory Status | Mateon Therapeutics files an IND application with the US FDA in for COVID-2019 infections [62] Updated 30 Apr 2020 |
| 09 Apr 2020 | Regulatory Status | Mateon Therapeutics files a pre-IND application with the US FDA for COVID-19 [63] Updated 09 Apr 2020 |
| 25 Mar 2020 | Regulatory Status | Mateon Therapeutics announces intention to submit IND application to the US FDA for COVID-2019 infections [65] Updated 27 Mar 2020 |
| 18 Mar 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019 infections in USA (Parenteral) prior to March 2020 [1] Updated 20 Mar 2020 |
| 18 Mar 2020 | Regulatory Status | Mateon Therapeutics intends to work with the US FDA to conduct clinical trials of Trabedersen for COVID-19 infections [1] Updated 20 Mar 2020 |
| 18 Mar 2020 | Trial Update | Mateon Therapeutics plans clinical trials for COVID-19 infections [1] Updated 20 Mar 2020 |
| 02 Mar 2020 | Phase Change - Preclinical | Preclinical trials in COVID-19 pneumonia in USA (Parenteral) [67] Updated 06 Mar 2020 |
| 03 Feb 2020 | Licensing Status | Golden Mountain Partners (GMP) and Mateon Therapeutics enter into research and service Agreement for clinical development in COVID-19 infections [14] Updated 25 Jun 2020 |
| 23 Sep 2019 | Regulatory Status | The US FDA grants Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma [34] Updated 25 Sep 2019 |
| 09 Sep 2019 | Trial Update | Mateon Therapeutics plans a expanded access program for Pancreatic cancer Updated 12 Sep 2019 |
| 25 Apr 2019 | Company Involvement | Oncotelic has been acquired by Mateon Therapeutics Updated 02 May 2019 |
| 25 Apr 2019 | Trial Update | Oncotelic plans multiple phase III registration trials of OT 101 in Glioblastoma and Pancreatic cancer [3] Updated 30 Apr 2019 |
| 29 Mar 2019 | Scientific Update | Updated safety data from a phase IIb trial in Glioma presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019) [26] Updated 18 Apr 2019 |
| 29 Mar 2019 | Scientific Update | Updated efficacy data from a phase I/II trial in Pancreatic cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019) [42] Updated 16 Apr 2019 |
| 15 Feb 2019 | Biomarker Update | Biomarkers information updated Updated 17 Sep 2021 |
| 08 Sep 2017 | Licensing Status | Novosom re-acquires SMARTICLES technology from Marina Biotech (AdheraTherapeutics) [9] Updated 11 May 2021 |
| 08 Sep 2017 | Scientific Update | Pharmacodynamics data from a preclinical trial in Malignant melanoma, Pancreatic cancer, Glioblastoma and Ovarian cancer (Combination therapy) presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017) [55] Updated 16 Oct 2017 |
| 08 Sep 2017 | Phase Change - Preclinical | Preclinical trials in Pancreatic cancer, Ovarian cancer, Glioblastoma and Malignant melanoma (Combination therapy) in USA (IV) [55] Updated 14 Oct 2017 |
| 31 Aug 2017 | Scientific Update | Efficacy and pharmacokinetic data from a phase I/II trial in Pancreatic cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017) [41] Updated 11 Oct 2017 |
| 17 Jul 2017 | Licensing Status | Oncotelic in-licenses conformationally restricted nucleotide (CRN) technology from Marina Biotech [11] Updated 31 Jul 2017 |
| 01 Apr 2017 | Scientific Update | Pharmacokinetics data from a phase I/II trial in Malignant melanoma, Pancreatic cancer and Colorectal cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017) [36] Updated 19 Apr 2017 |
| 07 Sep 2016 | Active Status Review | Trabedersen is still in phase II/III trials for Glioblastoma in Georgia and Israel (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Active Status Review | Trabedersen is still in phase II/III trials for Malignant melanoma in Germany (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Active Status Review | Trabedersen is still in phase II/III trials for Pancreatic cancer in Germany (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Active Status Review | Trabedersen is still in phase III trials for Glioblastoma in Argentina, Austria, Brazil, France, Germany, Hungary, India, Poland, Russia, South Korea, Spain, Taiwan, USA and United Kingdom (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Phase Change - Discontinued(II) | Discontinued - Phase-II for Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Israel, Georgia (Intratumoural) (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Phase Change - Discontinued(III) | Discontinued - Phase-III for Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in United Kingdom, Taiwan, Spain, Poland, South Korea, Hungary, France, Brazil, Argentina, USA, India, Russia, Germany, Mexico, Canada, Austria (Intratumoural) (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Phase Change - II/III | Phase-II/III clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Georgia, Israel (Intratumoural) before September 2016 (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Phase Change - II/III | Phase-II/III clinical trials in Malignant melanoma (Second-line therapy or greater) in Germany (IV) before September 2016 (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 07 Sep 2016 | Phase Change - II/III | Phase-II/III clinical trials in Pancreatic cancer (Second-line therapy or greater) in Germany (IV) before September 2016 (Oncotelic pipeline, September 2016) Updated 07 Sep 2016 |
| 02 Sep 2016 | Scientific Update | Efficacy data from a phase I/II trial in Pancreatic cancer released by Oncotelic [37] Updated 09 Sep 2016 |
| 02 Sep 2016 | Trial Update | Oncotelic and Autotelic plan multiple phase II combination trials and pivotal phase III trials for Pancreatic cancer, Melanoma and Glioblastoma [37] [3] Updated 09 Sep 2016 |
| 16 Apr 2016 | Scientific Update | Efficacy data from a phase I trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) [72] Updated 19 Apr 2016 |
| 09 Mar 2016 | Scientific Update | Efficacy data from a phase I/II trial in Malignant melanoma released by Oncotelic [38] Updated 09 Sep 2016 |
| 09 Feb 2016 | Scientific Update | Pharmacodynamics data from a preclinical trial in Solid tumours released by Oncotelics [44] Updated 09 Sep 2016 |
| 14 Oct 2015 | Licensing Status | Autotelic acquires trabedersen from Antisense Pharma [15] Updated 07 Sep 2016 |
| 11 Aug 2015 | Phase Change - No development reported(I/II) | No recent reports on development identified - Phase-I/II for Colorectal cancer (Second-line therapy or greater), Pancreatic cancer (Second-line therapy or greater) and Malignant melanoma (Second-line therapy or greater) in Germany (IV) Updated 11 Aug 2015 |
| 04 Nov 2014 | Trial Update | Isarna Therapeutics terminates phase III trial in Glioblastoma and Anaplastic astrocytoma in USA, Argentina, Austria, Brazil, France, Germany, Hungary, India, Poland, Russia, South Korea, Spain, Taiwan and United Kingdom (NCT00761280) Updated 07 Sep 2016 |
| 31 Oct 2014 | Licensing Status | Trabedersen is available for licensing to a regional partner - http://www.isarna-therapeutics.com Updated 13 Jan 2015 |
| 26 Oct 2013 | Company Involvement | Antisense Pharma is now called Isarna Therapeutics Updated 26 Oct 2013 |
| 30 Sep 2013 | Phase Change - Preclinical | Preclinical trials in Cancer in Germany (IV) Updated 18 Apr 2012 |
| 28 Mar 2012 | Phase Change - Discontinued(III) | Discontinued - Phase-III for Anaplastic astrocytoma/Glioblastoma in Asia (Intratumoural) Updated 18 Apr 2012 |
| 28 Mar 2012 | Phase Change - Discontinued(III) | Discontinued - Phase-III for Anaplastic astrocytoma/Glioblastoma in Canada (Intratumoural) Updated 18 Apr 2012 |
| 28 Mar 2012 | Phase Change - Discontinued(III) | Discontinued - Phase-III for Anaplastic astrocytoma/Glioblastoma in Europe (Intratumoural) Updated 18 Apr 2012 |
| 28 Mar 2012 | Phase Change - Discontinued(III) | Discontinued - Phase-III for Anaplastic astrocytoma/Glioblastoma in Mexico (Intratumoural) Updated 18 Apr 2012 |
| 18 Nov 2011 | Trial Update | Antisense Pharma completes a phase I/II trial in Malignant melanoma, pancreatic cancer and colorectal cancer in Germany (NCT00844064) Updated 18 Jan 2012 |
| 22 Aug 2011 | Regulatory Status | Trabedersen - Autotelic/Oncotelic receives Orphan Drug status for Malignant melanoma (Late-stage disease) in USA [45] Updated 23 Mar 2021 |
| 06 Apr 2011 | Scientific Update | Interim safety and efficacy data from a phase I/II trial in Solid tumours presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011) [73] Updated 21 Apr 2011 |
| 16 Nov 2010 | Scientific Update | Preclinical pharmacodynamics data presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010) [74] , [75] Updated 03 Dec 2010 |
| 10 Nov 2010 | Trial Update | Antisense Pharma completes enrolment in its phase I/II trial for Malignant melanoma, pancreatic cancer & colorectal cancer in Germany (NCT00844064) Updated 28 Apr 2011 |
| 08 Nov 2010 | Licensing Status | Trabedersen is available for licensing in USA, Japan, Europe as of 03 Feb 2003. http://www.antisense-pharma.com Updated 08 Nov 2010 |
| 20 Apr 2010 | Scientific Update | Two-year efficacy data from a phase IIb trial in Glioma presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010) [76] Updated 10 May 2010 |
| 19 Oct 2009 | Regulatory Status | Antisense Pharma receives approval from Health Canada for the phase III SAPPHIRE trial in anaplastic astrocytoma [23] Updated 21 Oct 2009 |
| 14 Sep 2009 | Regulatory Status | Trabedersen received Orphan Drug status for Pancreatic cancer in European Union Updated 16 Sep 2009 |
| 14 Sep 2009 | Regulatory Status | Trabedersen received Orphan Drug status for Pancreatic cancer in USA Updated 16 Sep 2009 |
| 02 Jun 2009 | Scientific Update | Interim efficacy data from a phase I trial in Solid tumours presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009) Updated 10 Jun 2009 |
| 01 Jun 2009 | Scientific Update | Efficacy data from a phase IIb trial in Glioma presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009) [27] Updated 22 Jun 2009 |
| 27 Apr 2009 | Phase Change - III | Phase-III clinical trials in Anaplastic astrocytoma in Asia (Intratumoural) Updated 28 Apr 2009 |
| 22 Apr 2009 | Scientific Update | Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) [77] Updated 14 May 2009 |
| 01 Mar 2009 | Trial Update | Iserna Therapeutics completes a phase II trial in Glioblastoma and Anaplastic astrocytoma in Austria, Georgia, Germany, India, Israel and Russia (NCT00431561) Updated 07 Sep 2016 |
| 31 Dec 2008 | Phase Change - III | Phase-III clinical trials in Anaplastic astrocytoma in Mexico (Intratumoural) Updated 21 Oct 2009 |
| 31 Dec 2008 | Phase Change - III | Phase-III clinical trials in Anaplastic astrocytoma in Canada (Intratumoural) Updated 04 Mar 2009 |
| 31 Dec 2008 | Phase Change - III | Phase-III clinical trials in Anaplastic astrocytoma in Europe (Intratumoural) Updated 04 Mar 2009 |
| 01 Dec 2008 | Phase Change - III | Phase-III clinical trials in Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in India, Russia, Germany (Intratumoural) (NCT00761280) Updated 07 Sep 2016 |
| 01 Dec 2008 | Phase Change - III | Phase-III clinical trials in Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in United Kingdom, Taiwan, Spain, Poland, South Korea, Hungary, France, Brazil, Argentina, USA (Intratumoural) (NCT00761280) Updated 07 Sep 2016 |
| 01 Dec 2008 | Phase Change - III | Phase-III clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Austria, India, Germany, Russia (Intratumoural) (NCT00761280) Updated 07 Sep 2016 |
| 01 Dec 2008 | Phase Change - III | Phase-III clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in United Kingdom, Taiwan, Spain, Poland, South Korea, Hungary, France, Brazil, Argentina, USA (Intratumoural) (NCT00761280) Updated 07 Sep 2016 |
| 03 Jun 2008 | Scientific Update | Interim adverse events and efficacy data from a phase II study in recurrent or refractory Glioblastoma, including anaplastic astrocytoma, and a phase I/II trial in Solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008) [29] , [78] , [30] , [31] , [39] Updated 10 Jun 2008 |
| 06 Jul 2007 | Scientific Update | Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections [79] Updated 06 Jul 2007 |
| 01 Feb 2007 | Licensing Status | AP 12009 is available for licensing in the USA, Europe and Japan for high-grade glioma and pancreatic cancer (http://www.antisense-pharma.com) Updated 01 Feb 2007 |
| 01 Feb 2007 | Phase Change - Discontinued(I/II) | Discontinued - Phase-I/II for Glioblastoma in Germany (Intratumoural) Updated 01 Feb 2007 |
| 01 Feb 2007 | Phase Change - Discontinued(II) | Discontinued - Phase-II for Glioblastoma in India (Intratumoural) Updated 01 Feb 2007 |
| 01 Feb 2007 | Phase Change - Discontinued(II) | Discontinued - Phase-II for Glioblastoma in Israel (Intratumoural) Updated 01 Feb 2007 |
| 05 Dec 2006 | Phase Change - II | Phase-II clinical trials in Anaplastic astrocytoma in Europe (Intratumoural) Updated 05 Dec 2007 |
| 05 Dec 2006 | Phase Change - II | Phase-II clinical trials in Anaplastic astrocytoma in Germany (Intratumoural) Updated 05 Dec 2007 |
| 01 Dec 2006 | Scientific Update | Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer therapeutic trials section [80] Updated 01 Dec 2006 |
| 18 May 2006 | Phase Change - I/II | Phase-I/II clinical trials in Colorectal cancer in Germany (Intratumoural) Updated 09 Jun 2006 |
| 18 May 2006 | Phase Change - I/II | Phase-I/II clinical trials in Malignant melanoma in Germany (Intratumoural) Updated 09 Jun 2006 |
| 30 Nov 2005 | Other | Antisense Pharma raised $US18 million in private equity from German venture capital investor MIG Funds Updated 05 Dec 2005 |
| 06 May 2005 | Trial Update | Antisense Pharma has completed enrolment in a phase IIb trial for high grade glioma in Germany Updated 06 May 2005 |
| 04 May 2005 | Phase Change - I/II | Phase-I/II clinical trials in Pancreatic cancer in Germany (Intratumoural) Updated 04 May 2005 |
| 04 May 2005 | Scientific Update | Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section [81] Updated 04 May 2005 |
| 07 Jul 2004 | Phase Change - II/III | Phase-II/III clinical trials in Glioblastoma in Europe (Intratumoural) Updated 09 Jul 2004 |
| 18 May 2004 | Scientific Update | Data presented at the 56th Annual Meeting of the American Academy of Neurology (AAN-2004) have been added to the Cancer therapeutic trials section [82] Updated 18 May 2004 |
| 09 Oct 2003 | Scientific Update | Data presented at the 12th European Cancer Conference (ECCO-2003) have been added to the adverse events and therapeutic trials sections [83] Updated 09 Oct 2003 |
| 01 Sep 2003 | Phase Change - II | Phase-II clinical trials in Glioblastoma in Europe (Intratumoural) Updated 01 Sep 2003 |
| 01 Sep 2003 | Phase Change - II | Phase-II clinical trials in Glioblastoma in India (Intratumoural) Updated 01 Sep 2003 |
| 01 Sep 2003 | Phase Change - II | Phase-II clinical trials in Glioblastoma in Israel (Intratumoural) Updated 01 Sep 2003 |
| 01 Sep 2003 | Scientific Update | Data from a media release have been added to the Cancer therapeutic trials section [84] Updated 01 Sep 2003 |
| 01 Apr 2003 | Phase Change - II | Phase-II clinical trials in Anaplastic astrocytoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Russia, Israel, India, Georgia (Intratumoural) (NCT00431561) Updated 07 Sep 2016 |
| 01 Apr 2003 | Phase Change - II | Phase-II clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Russia, Germany, Georgia (Intratumoural) (NCT00431561) Updated 07 Sep 2016 |
| 11 Mar 2003 | Scientific Update | A study has been added to the Cancer therapeutic trials section [33] Updated 11 Mar 2003 |
| 03 Feb 2003 | Licensing Status | AP 12009 is available for licensing for the treatment of Glioma (http://www.antisense-pharma.de/) Updated 03 Feb 2003 |
| 09 Oct 2002 | Scientific Update | A clinical study has been added to the adverse events section [33] Updated 09 Oct 2002 |
| 09 Oct 2002 | Scientific Update | A preclinical study has been added to the adverse events section [85] Updated 09 Oct 2002 |
| 09 Oct 2002 | Scientific Update | A preclinical study has been added to the Cancer pharmacodynamics section [86] Updated 09 Oct 2002 |
| 22 Jul 2002 | Regulatory Status | AP 12009 has received Orphan Drug Status for high grade glioma in the USA Updated 22 Jul 2002 |
| 18 Apr 2002 | Regulatory Status | AP 12009 has received Orphan Drug Status for high grade glioma in the EU Updated 18 Apr 2002 |
| 16 Jul 2001 | Phase Change - I/II | Phase-I/II clinical trials for High-grade glioma in Germany and Europe (Intratumoural administration) Updated 16 Jul 2001 |
References
-
Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19.
Media Release -
Antisense Pharma Changes Name to Isarna Therapeutics.
Media Release -
MATEON AND ONCOTELIC COMPLETE THEIR MERGER AND CREATE A NEW IMMUNO-ONCOLOGY COMPANY WITH A LATE-STAGE CLINICAL ASSET AGAINST CANCER AND A PROMISING PRODUCT PIPELINE .
Media Release -
ONCOTELIC THERAPEUTICS, INC. (FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE.
Media Release -
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction.
Media Release -
Oncotelic Therapeutics SEC Filling. Internet-Doc 2023;.
Available from: URL: https://www.sec.gov/ix?doc=/Archives/edgar/data/908259/000149315223012352/form10-k.htm -
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID.
Media Release -
Marina Biotech Acquires RNA Delivery Assets of Novosom AG.
Media Release -
Form-10-K; Adhera therapeutics; For the fiscal year ended December 31, 2020. Internet-Doc 2021;.
Available from: URL: https://www.sec.gov/ix?doc=/Archives/edgar/data/737207/000149315221008190/form10-k.htm -
Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics.
Media Release -
Marina Biotech 8-K, filed 21 July 2017. Internet-Doc 2017;.
Available from: URL: https://www.sec.gov/Archives/edgar/data/737207/000149315217008096/form8-k.htm -
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes.
Media Release -
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO.
Media Release -
Mateon and GMP Completed Research and Service Agreement.
Media Release -
Isarna Therapeutics and Autotelic Signed Asset Sale and Purchase Agreement for Trabedersen.
Media Release -
A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
ctiprofile -
Invitation to Participate in STOP-PC Clinical Trial.
Media Release -
Sapu BioScience and Cromos Pharma initiating P201 - A Registrational trial for OT-101 in Pancreatic Cancer.
Media Release -
Oncotelic Participating at 2023 BIO International Convention.
Media Release -
A Randomized Phase 2b/Phase 3 P201 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination with FOLFIRINOX Compared with FOLFIRINOX Alone as second-line therapy in Patients with Metastatic Pancreatic Cancer
ctiprofile -
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer.
Media Release -
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas.
Media Release -
Health Canada approves Antisense Pharma's clinical Phase III study SAPPHIRE in aggressive brain tumors.
Media Release -
Antisense Pharma Begins Pivotal Phase III Clinical Trial with Trabedersen in Aggressive Brain Tumors.
Media Release -
Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
ctiprofile -
Hwang L, Nam D, Uckun F, Trieu V. OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy. AACR-2019 2019; abstr. 5029 / 23.
Available from: URL: http://www.abstractsonline.com/pp8/#!/6812/presentation/3266 -
Bogdahn U, Schneider T, Oliushine V, Parfenov V, Mahapatra AK, Balasubramaniam A, et al. Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: basis for phase III endpoints. 45th-ASCO-2009 2009;96 abstr. 2037.
Available from: URL: http://www.abstract.asco.org -
Antisense Pharma Completes Patient Recruitment for AP 12009 Phase II Trial.
Media Release -
Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements.
Media Release -
Bogdahn U, Mahapatra AK, Olyushin V, Parfenov V, Stockhammer G, Ludwig S, et al. Results of a phase IIb active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma. 44th-Ann-Meet-Am-Soc-Clin-Oncol 2008; abstr. 2076.
Available from: URL: http://www.asco.org -
Bogdahn U, Hau P, Olyushin V, Mahapatra AK, Parfenov V, Venkataramana NK, et al. Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase IIb study. 44th-Ann-Meet-Am-Soc-Clin-Oncol 2008; abstr. 2018.
Available from: URL: http://www.asco.org -
Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week
ctiprofile -
Hau P, Bogdahn U, Steinbrecher A, Zellner A, Schulmeyer F, et al. Results of clinical I/II dose escalation study using the TGF-beta-2 antisense oligonucleotide AP12009 administered intratumorally to patients with high-grade glioma. Neuro-Oncol 2002;4 (Suppl. 1)abstr. 181.
-
FDA GRANTS PEDIATRIC DISEASE DESIGNATION FOR MATEON'S OT101.
Media Release -
An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-beta2
ctiprofile -
Wang W, Ng K, Nam D, Trieu V, Hwang L. Population pharmacokinetic model for OT-101 - A TGF-beta2-specific antisense oligonucleotide in cancer patients. AACR-2017 2017; abstr. 5043 /18.
Available from: URL: http://www.abstractsonline.com/pp8#!/4292/presentation/1258 -
Oncotelic Inc. and Autotelic Inc. Announce Clinical Data Supporting IL-8 Spike as a Prognostic Biomarker for Immunotherapy.
Media Release -
Oncotelic Release: Results Of A Phase I/II Trial Of Ot-101 In Advanced Melanoma Patients.
Media Release -
Hilbig A, Seufferlein T, Schmid RM, Luger T, Oettle H, Schneider G, et al. Preliminary results of a phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009. 44th-Ann-Meet-Am-Soc-Clin-Oncol 2008; abstr. 4621.
Available from: URL: http://www.asco.org -
Phase I/II-trial expanded: TGF-beta2-Inhibitor AP 12009 for Colorectal Carcinoma and Malignant Melanoma Patients.
Media Release -
Hwang L, Wang W, Qazi S, Ng K, D?cruz O, Trieu V. IL-8 as a pharmacodynamic biomarker for TGF- b 2 antisense (trabedersen) therapy: Results of a phase II trial. ESMO-2017 2017; abstr. 119P.
Available from: URL: http://www.esmo.org/Conferences/ESMO-2017-Congress -
Nam D, Hwang L, Trieu V. OT-101/Chemotherapy - A novel mechanism of action (MOA) in pancreatic cancer immunization therapy. AACR-2019 2019; abstr. 3968 / 24.
-
OT-101 PRESENTATION AT PHARMA FORUM 2020 .
Media Release -
Oncotelic Presents The Synergy Of OT-101 (A Late Stage TGF beta inhibitor) And A Chemotherapy Agent.
Media Release -
ODD-Maligant melonoma. Internet-Doc 2021;.
Available from: URL: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=346011 -
FDA and EMEA Grant Orphan Drug Designation for Antisense Pharma's Investigational Drug Trabedersen in Pancreatic Carcinoma.
Media Release -
Phase 2 Trial of TGF-β2 Inhibition (OT-101) With Atezolizumab as Second-Line or Third-Line Therapy for Patients Previously Treated With Immunotherapy (+/- Chemotherapy) With Metastatic Non-Small Cell Lung Cancer (NSCLC)
ctiprofile -
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer.
Media Release -
Oncotelic Presenting at BiotechGate Digital Partnering.
Media Release -
A phase 1b study of OT-101 in combination of IL-2
ctiprofile -
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201).
Media Release -
Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA(R) for Mesothelioma.
Media Release -
ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021.
Media Release -
MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS.
Media Release -
D?Cruz O, Lee C, Trieu V, Hwang L. Synergistic antitumor effects of OT-101 (trabedersen), a transforming growth factor-beta 2 (TGF- b 2) antisense oligonucleotide (ASO) and chemotherapy in preclinical tumor models. ESMO-2017 2017; abstr. 1662P.
Available from: URL: http://www.esmo.org/Conferences/ESMO-2017-Congress -
ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.
Media Release -
A Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia
ctiprofile -
MATEON'S GLOBAL STUDY FOR OT-101/ TGF-##914## INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT.
Media Release -
MATEON'S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19.
Media Release -
ONCOTELIC PROVIDES 3RD QUARTER 2021 COMPARED TO 3RD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE.
Media Release -
Mateon Provides Update on OT-101.
Media Release -
Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients.
Media Release -
Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19.
Media Release -
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients.
Media Release -
Mateon Report Positive Results for Multiple COVID-19 Drug Candidates.
Media Release -
Mateon Provides Update on its R&D Effort Against COVID-19.
Media Release -
Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19.
Media Release -
MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19.
Media Release -
SEC filing_Oncotelic Therapeutics_For the fiscal year ended December 31, 2020. Internet-Doc 2021;.
Available from: URL: https://www.sec.gov/Archives/edgar/data/908259/000149315221008920/form10-k.htm -
Oncotelic Issues Year End Message to Shareholders.
Media Release -
ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDY.
Media Release -
Hwang L, Ng K, Wang W, Trieu V. Treatment with trabedersen, an anti-TGF-beta 2 antisense, primed tumors to subsequent chemotherapies. AACR-2016 2016; abstr. 3742.
Available from: URL: http://www.abstractsonline.com/plan/AbstractPrintView.aspx?mID=4017&sKey=3a94392d-66ff-4ac6-83b6-76c058b689b1&cKey=ee8eba72-5806-47af-98dd-e65142d5c25b&mkey=%7b1D10D749-4B6A-4AB3-BCD4-F80FB1922267%7d -
Oettle H, Hilbig A, Seufferlein T, Luger T, Schmid R, von Wichert G, et al. Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study. 102nd-AACR-2011 2011; abstr. 5506.
Available from: URL: http://www.aacr.org -
Jaschinski F, Kielmanowicz M, Rothhammer T, Schneider A, Schlingensiepen KH. Effect of the TGF-beta 2 specific antisense oligodeoxynucleotide trabedersen on TGF-beta 2 and -beta 1 expression in human glioma cells: Cross-regulatory loops regulate TGF-beta isoform expression. 22nd-EORTC-NCI-AACR-2010 2010; abstr. 359.
Available from: URL: http://www.ecco-org.eu -
Jaschinski F, Lang SA, Moser C, Schlitt HJ, Schneider A, Schlingensiepen KH. Activity of the TGF-beta 2 specific antisense oligodeoxynucleotide trabedersen in an orthotopic xenograft mouse model of metastatic pancreatic cancer. 22nd-EORTC-NCI-AACR-2010 2010; abstr. 530.
Available from: URL: http://www.ecco-org.eu -
Jachimczak P, Schlingensiepen K-H, Heinrichs H, Bogdahn U, AP study group. Targeted therapy of high-grade gliomas using TGF-beta2 inhibitor trabedersen (AP 12009): Results of the Phase IIb study as basis for the Phase III SAPPHIRE Study. 101st-AACR-2010 2010; abstr. 3716.
Available from: URL: http://www.abstractsonline.com -
Jaschinski F, Rothhammer T, Fischer D, Kick C, Kielmanowicz M, Jachimczak P, et al. TGF-beta-2 antisense oligonucleotide AP 12009 (trabedersen) as a therapeutic agent in colorectal cancer. 100th-AACR-2009 2009; abstr. 845.
Available from: URL: http://www.aacr.org -
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma.
Media Release -
Bogdahn U, Mahapatra A, Olyushin VE, Mouli C, Parfenov VE, Stockhammer G, et al. A phase IIb actively controlled study with the TGF-beta-2 inhibitor AP 12009 for recurrent or refractory anaplastic astrocytoma. J-Clin-Oncol 2007;25 (Suppl.)(18):81.
-
Bogdahn U, Zaaroor M, Parfenov VE, Kunst M, Mahapatra AK, Sastry KVR, et al. A phase IIb study in patients with recurrent malignant glioma with the TGF-beta-2 inhibitor AP 12009. EJC-Suppl 2006;4(12):103.
-
Schlingensiepen K-H, Bischof A, Fischer D, Egger T, Hafner M, et al. The TGF-beta-2 antisense oligonucleotide AP 12009 as a therapeutic agent in pancreatic cancer: evaluation of the safety and tolerability in a phase I/II dose escalation study. 96th-AACR 2005;46789.
-
Bogdahn U, Hau P, Brawanski A, Schlaier J, Mehdorn M, et al. TGF-beta-2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies. Neurology 2004;62 (Suppl. 5)(7):542-543.
-
Hau P, Bogdahn U, Schlaier J, Mehdorn M, Wurm G, et al. The TGF-beta-2 antisense oligonucleotide AP 12009 as a therapeutic agent in recurrent high-grade glioma: safety and efficacy results of phase I/II clinical trials. EJC-Suppl 2003;1(5):14 abstr. 34.
-
Complete Clinical Results of Phase I/II Studies with AP 12009 for Glioma will be presented at 2003 Annual Meeting of ASCO.
Media Release -
Stauder G, Schlingensiepen KH, Goldbrunner M, Jachimczak P, Schulmeyer F, et al. Results of safety pharmacology and toxicological studies with the TGF-beta-2 antisense oligonucleotide AP 12009. Neuro-Oncol 2002;4 (Suppl. 1)abstr. 399.
-
Iachimczak P, Schlingensiepen KH, Schlingensiepen R, Bischof A, Hafner M, et al. Antisense oligonucleotide AP 12009 specific for nRNA encoding human transforming growth factor beta-2 in the therapy of malignant gliomas in vitro. Neuro-Oncol 2002;4 (Suppl. 1)abstr. 206.
-
Stauder GM, Schlingensiepen R, Goldbrunner M, Bischof A, Kunst M, et al. Safety pharmacology and toxicity studies of the TGF-beta-2 antisense oligonucleotide AP 12009. 38th-Proc-Am-Soc-Clin-Oncol 2002;2122.
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG